MEDRx said on March 25 that a new drug application has been filed with the US FDA for MRX-5LBT (Lydolyte), a lidocaine patch being developed jointly with D. Western Therapeutics Institute for the treatment of post-herpetic neuralgia. This marks the…
To read the full story
Related Article
- MEDRx/DWTI Clinch US FDA Approval for Lidocaine Patch
September 26, 2025
- FDA Snubs MEDRx/DWTI’s Lidocaine Patch Yet Again
July 16, 2024
- FDA Gives Thumbs-Down for MEDRx/DWTI’s Lidocaine Patch
October 3, 2023
BUSINESS
- Alexion CEO Calls Japan “Special” for Rare Disease Drug Development
July 9, 2026
- Towa Seeks Policy Reset on Off-Patent Meds, Says Generic Push Has Run Its Course
July 9, 2026
- Ipsen Rolls Out Japan’s First FOP Treatment Sohonos
July 9, 2026
- Fujifilm Picked for FDA Pilot to Accelerate US CDMO Expansion
July 9, 2026
- Nichi-Iko Exits Turnaround Mode, Eyes Next Growth Phase
July 9, 2026
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…





